Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neuro intensive care unit
Given the conclusion that intravenous efgartigimod is a non-invasive fast-acting treatment with fewer AEs, this may provide NICU workers with another option for managing patients with MC.
Authors
- Xiaofei Sun (ORCID: https://orcid.org/0000-0002-7724-6063)
- Feng Li (ORCID: https://orcid.org/0000-0001-8184-1247)
- Hongyan Zhou (ORCID: https://orcid.org/0000-0002-4210-3476)
- Huiyu Feng (ORCID: https://orcid.org/0000-0003-1153-5919)
- Zhilong Xu
- Cunzhou Shen
- Haiyan Wang (ORCID: https://orcid.org/0009-0001-7246-431X)
- Fu‐Dong Shi (ORCID: https://orcid.org/0000-0002-9675-4637)
- Jiezhen Feng
- Rong Lai
Institutions
- Sun Yat-sen University (CN)
Publication Details
- Journal
- BMC Neurology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1186/s12883-025-04063-1
- Citations
- 4
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 5.56
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province